Reality on the ground:
- 6 quarters of cash remaining.
- Cash outflow accelerated over the past two quarters: from -3 to -5 and now -6. The rest is cheap talk
- Can you find quarterly receipts in this report? I wonder why: Q1: 3.1 => Q2: 2.9 => Q3: 2.6. Here we go with growth. What a spectacular FFFF.
- Operational numbers minimal: clinical data and the ridiculous accumulative tests (slide #15) are presented instead. The arrow in slide #15 insults the reader: you expected the accumulative number of tests to decline? I can smell duplicity, weakness, and hiding from where I am sitting (which is quite distant).
For me, it's time to wear the big boys' pants, sell, and cut losses.
Add to My Watchlist
What is My Watchlist?
